Trinity Technologies reintroducing generic drugs
Executive Summary
The Roseville, Michigan-based firm will have six generic drug products re-entering the market by January. The company voluntarily suspended manufacturing and distribution in August 1993 to address compliance problems, mainly related to process validation ("The Pink Sheet" Aug. 16, 1993, T&G-14). Trinity received additional capital for state-of-the-art manufacturing and processing equipment when it was acquired in March by Therapharm Holdings, Inc. Trinity expects to file several ANDAs in 1995 for long acting and narrow therapeutic range drugs
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth